The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis

BACKGROUND AND PURPOSE: Apatinib is a novel, oral, small-molecule tyrosine kinase inhibitor that targets VEGFR-2. Recent clinical trials have revealed its broad-spectrum anticancer effect. However, most recent studies of apatinib have involved single-arm studies with insufficient cases, different do...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Dantong, Hou, Helei, Zhang, Chuantao, Zhang, Xiaochun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178936/
https://www.ncbi.nlm.nih.gov/pubmed/30323627
http://dx.doi.org/10.2147/OTT.S176429

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178936/
https://www.ncbi.nlm.nih.gov/pubmed/30323627
http://dx.doi.org/10.2147/OTT.S176429

Ejemplares similares